Volume 1, # 12 - April, 1996
Table of Contents
|
| VOLUME I REVIEW |
| Oncology Drugs Market Trends |
265 |
| Prices Rise in the USA |
265 |
| Oncology Drug Revenues Grow |
265 |
| Regulatory Developments |
266 |
| Acceleration of Oncology Drug Approvals |
266 |
| Less Restrictive Dissemination of Oncology Product Information |
266 |
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
|
| Esophageal Cancer |
266 |
| Epidemiology Update |
266 |
| Drug Approval |
271 |
| QLT PhotoTherapeutics |
271 |
| Colorectal Cancer |
273 |
| Epidemiology Update |
273 |
| Drug Approvals |
273 |
| Zeneca |
274 |
| Rhône-Poulenc Rorer |
274 |
| MECHANISMS IN MALIGNANCY |
|
| Apoptosis |
274 |
| New Findings |
274 |
| Apoptosis Technology |
274 |
| Apoptosis Mediating Drugs in Development |
274 |
| Milkhaus Laboratory |
274 |
| Angiogenesis |
274 |
| Angiogenesis in the Assessment of Cancer |
274 |
| Angiogenesis-based Therapeutics |
275 |
| Angiogenesis Technologies |
275 |
| EntreMed |
275 |
| Texas Biotechnology |
275 |
| Other Developments |
275 |
| ANTICANCER DRUGS AND MARKETS |
|
| Taxanes |
275 |
| Paclitaxel |
275 |
| Docetaxel |
276 |
| Platinum-based Drugs |
276 |
| JM-216 |
276 |
| TECHNOLOGY UPDATE |
|
| Radiopharmaceuticals in Cancer Diagnosis |
276 |
| USA Markets |
276 |
| Market estimates and forecasts |
276 |
| Distribution trends |
276 |
| Pricing trends |
276 |
| Agents Approved, Recommended or in Development for Cancer Imaging |
276 |
| Antisoma |
277 |
| Biomira |
277 |
| Cytogen |
277 |
| Diatide |
278 |
| DuPont Merck Pharmaceutical |
278 |
| Immunomedics |
278 |
| Neoprobe |
278 |
| NeoRx |
279 |
| Nycomed Imaging |
279 |
| Resolution Pharmaceuticals |
279 |
| Syncor International |
276 |
